Publicaciones en las que colabora con ROSA MARÍA PÉREZ GOMÁRIZ (66)

2018

  1. Inhibitory role of growth hormone in the induction and progression phases of collagen-induced arthritis

    Frontiers in Immunology, Vol. 9, Núm. MAY

2016

  1. Healthy and Osteoarthritic Synovial Fibroblasts Produce a Disintegrin and Metalloproteinase with Thrombospondin Motifs 4, 5, 7, and 12: Induction by IL-1β and Fibronectin and Contribution to Cartilage Damage

    American Journal of Pathology, Vol. 186, Núm. 9, pp. 2449-2461

2015

  1. Th17 polarization of memory Th cells in early arthritis: The vasoactive intestinal peptide effect

    Journal of Leukocyte Biology, Vol. 98, Núm. 2, pp. 257-269

  2. The pathogenic Th profile of human activated memory Th cells in early rheumatoid arthritis can be modulated by VIP

    Journal of Molecular Medicine, Vol. 93, Núm. 4, pp. 457-467

2014

  1. Serum Levels of Vasoactive Intestinal Peptide as a Prognostic Marker in Early Arthritis

    PLoS ONE, Vol. 9, Núm. 1

  2. Vasoactive Intestinal Peptide Maintains the Nonpathogenic Profile of Human Th17-Polarized Cells

    Journal of Molecular Neuroscience, Vol. 54, Núm. 3, pp. 512-525

2012

  1. Effect of VIP on the balance between cytokines and master regulators of activated helper T cells

    Immunology and Cell Biology, Vol. 90, Núm. 2, pp. 178-186

  2. VIP in inflammatory bowel disease: State of the art

    Endocrine, Metabolic and Immune Disorders - Drug Targets, Vol. 12, Núm. 4, pp. 316-322

2011

  1. Differential expression pattern of pituitary adenylate cyclase-activating polypeptide (PACAP) alternative splicing variants and its receptors in the immune system of rainbow trout (Oncorhynchus mykiss)

    Fish and Shellfish Immunology, Vol. 30, Núm. 2, pp. 734-738

2010

  1. New insights into the role of VIP on the ratio of T-cell subsets during the development of autoimmune diabetes

    Immunology and Cell Biology, Vol. 88, Núm. 7, pp. 734-745

  2. Peptides targeting toll-like receptor signalling pathways for novel immune therapeutics

    Current Pharmaceutical Design, Vol. 16, Núm. 9, pp. 1063-1080

2009

  1. Pituitary adenylyl cyclase-activating polypeptide is an intrinsic regulator of Treg abundance and protects against experimental autoimmune encephalomyelitis

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 106, Núm. 6, pp. 2012-2017

2008

  1. Immunoregulatory properties of vasoactive intestinal peptide in human T cell subsets: Implications for rheumatoid arthritis

    Brain, Behavior, and Immunity, Vol. 22, Núm. 3, pp. 312-317

  2. VIP balances innate and adaptive immune responses induced by specific stimulation of TLR2 and TLR4

    Peptides, Vol. 29, Núm. 6, pp. 948-956

  3. Vasoactive intestinal peptide as a healing mediator in Crohn's disease

    NeuroImmunoModulation, Vol. 15, Núm. 1, pp. 46-53

2007

  1. Regulation of TLR expression, a new perspective for the role of VIP in immunity

    Peptides, Vol. 28, Núm. 9, pp. 1825-1832

  2. Vasoactive intestinal peptide regulates Th17 function in autoimmune inflammation

    NeuroImmunoModulation

2006

  1. Effect of VIP on TLR2 and TLR4 expression in lymph node immune cells during TNBS-induced colitis

    Annals of the New York Academy of Sciences

  2. PAC1 receptor: Emerging target for septic shock therapy

    Annals of the New York Academy of Sciences

  3. VIP and tolerance induction in autoimmunity

    Annals of the New York Academy of Sciences